• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC NEUROMODULATION IMPLANTABLE NEUROSTIMULATOR; STIMULATOR, ELECTRICAL, IMPLANTED, FOR PARKINS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC NEUROMODULATION IMPLANTABLE NEUROSTIMULATOR; STIMULATOR, ELECTRICAL, IMPLANTED, FOR PARKINS Back to Search Results
Model Number NEU_INS_STIMULATOR
Device Problems Adverse Event Without Identified Device or Use Problem (2993); Insufficient Information (3190)
Patient Problems Wound Dehiscence (1154); Stroke/CVA (1770); Sepsis (2067); Post Operative Wound Infection (2446); No Clinical Signs, Symptoms or Conditions (4582)
Event Date 12/22/2021
Event Type  Injury  
Event Description
Abstract/summary background: indications for deep brain stimulation (dbs) are rapidly growing within functional neurosurgery.The objective of this study was to characterize national trends in demographics and complications across distinct populations of dbs patients.Methods: we identified patients from the 2008¿2018 american college of surgeons national surgical quality improvement program (acs nsqip) participant use data file (puf) who underwent an implantation or revision procedure for dbs.Summary statistics for postoperative infection rate, noninfectious complication rate, total hospital length of stay, discharge disposition, mortality, reoperation or readmission, and time from operation to readmission were obtained.Patients were categorized by diagnosis for dbs treatment.Outcomes for each diagnosis group were compared to outcomes for the total study population.Results: dbs patients who underwent primary implantation procedures had low rates of postoperative infections (1.2%), noninfectious complications (0.8%), and mortality (0.1%) and a high likelihood of discharge home (97.6%).In addition, a large percentage of patients presented for revision or removal of neurostimulators (34.2% of cases) or treatment of long-term hardware infection (4.5%).Compared with patients with other diagnoses, patients with parkinson disease experienced lower rates of noninfectious complications (odds ratio 0.32; 95% ci, 0.15¿0.63; p = 0.002) and fewer unplanned reoperations (odds ratio 0.60; 95% ci, 0.39¿0.92; p = 0.02).Conclusion: analysis of a national database suggests that dbs is a relatively safe treatment across several different patient populations.These overall favorable results support the continued practice of dbs surgery and provide encouraging validation for increasing access to dbs therapy for new indications that are being actively investigated.Reported events: less than three patients implanted for other movement disorders experienced postoperative infection, which included sepsis, deep surgical site infection, superficial surgical site infection, and organ space surgical site infection.Less than one patient implanted for other movement disorders experienced noninfectious complications, which included stroke and wound disruption.Less than three patients implanted for other movement disorders experienced unplanned reoperation.Less than six patients implanted for other movement disorders experienced readmission within 30 days.Information regarding patient complications, readmission subcategories, and reoperations beyond 30 days after the procedure was not available.
 
Manufacturer Narrative
Kimata, a.R., koester, s.W., ma, k.L., catapano, j.S., zavala, b., whiting, a.C., ponce, f.A.Characterizing the trends in patient demographics, complications, and short-term outcomes after deep brain stimulation procedures.Interdisciplinary neurosurgery, 28, 101466.(2022).Doi: 10.1016/j.Inat.2021.101466.If information is provided in the future, a supplemental report will be issued.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
IMPLANTABLE NEUROSTIMULATOR
Type of Device
STIMULATOR, ELECTRICAL, IMPLANTED, FOR PARKINS
Manufacturer (Section D)
MEDTRONIC NEUROMODULATION
7000 central ave ne
minneapolis MN 55432
Manufacturer (Section G)
MEDTRONIC NEUROMODULATION
7000 central ave ne
minneapolis MN 55432
Manufacturer Contact
glen belmer
7000 central avenue ne rcw215
minneapolis, MN 55432
6122713209
MDR Report Key13794797
MDR Text Key292483703
Report Number2182207-2022-00446
Device Sequence Number1
Product Code MHY
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P960009
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Literature,Health Professional
Reporter Occupation Other
Type of Report Initial
Report Date 03/16/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/17/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model NumberNEU_INS_STIMULATOR
Device Catalogue NumberNEU_INS_STIMULATOR
Was Device Available for Evaluation? No
Date Manufacturer Received02/16/2022
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention; Life Threatening; Hospitalization;
Patient Age47 YR
Patient SexMale
-
-